Lumos Pharma Inc
General ticker "LUMO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $36.0M
Lumos Pharma Inc follows the US Stock Market performance with the rate: 24.2%.
Estimated limits based on current volatility of 0.3%: low 4.33$, high 4.35$
Factors to consider:
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.82$, 5.24$]
- 2024-12-30 to 2025-12-30 estimated range: [2.71$, 6.81$]
Financial Metrics affecting the LUMO estimates:
- Negative: Non-GAAP EPS, $ of -4.19 <= 0.10
- Negative: Operating profit margin, % of -94.70 <= 1.03
- Negative: Operating cash flow per share per price, % of -56.14 <= 2.35
- Negative: negative Net income
- Positive: Interest expense per share, $ of 0 <= 0
Short-term LUMO quotes
Long-term LUMO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.23MM | $1.52MM | $2.05MM |
| Operating Expenses | $31.58MM | $33.56MM | $38.66MM |
| Operating Income | $-31.35MM | $-32.04MM | $-36.61MM |
| Non-Operating Income | $0.28MM | $0.96MM | $2.55MM |
| Interest Expense | $0.00MM | $0.87MM | $0.00MM |
| R&D Expense | $16.25MM | $17.86MM | $22.10MM |
| Income(Loss) | $-31.07MM | $-31.07MM | $-34.06MM |
| Taxes | $-0.64MM | $-0.01MM | $-0.03MM |
| Profit(Loss) | $-30.43MM | $-31.06MM | $-34.03MM |
| Stockholders Equity | $88.98MM | $59.58MM | $27.30MM |
| Assets | $100.31MM | $72.29MM | $40.64MM |
| Operating Cash Flow | $-29.65MM | $-26.62MM | $-31.09MM |
| Capital expenditure | $0.03MM | $0.02MM | $0.00MM |
| Investing Cash Flow | $25.97MM | $-11.36MM | $10.74MM |
| Financing Cash Flow | $-0.19MM | $-0.82MM | $-0.58MM |
| Earnings Per Share* | $-3.65 | $-3.71 | $-4.18 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.